Dosing patterns and medication adherence in bipolar disorder patients treated with lurasidone: a US retrospective claims database analysis

Therapeutic Advances in Psychopharmacology

Volumn 6, Issue 6, 2016, Pages 355-368

  Sajatovic, Martha ^a   Ng Mak, Daisy ^b   Solem, Caitlyn T ^c   Lin, Fang Ju ^c   Rajagopalan, Krithika ^b   Loebel, Antony ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^c PHARMERIT INTERNATIONAL   (United States)

Author keywords

bipolar disorder; dosing; lurasidone; real world; retrospective database

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; LURASIDONE; MOOD STABILIZER; NEUROLEPTIC AGENT; QUETIAPINE; ZIPRASIDONE;

ADULT; ARTICLE; BIPOLAR DISORDER; COMORBIDITY; DRUG DOSE REGIMEN; FEMALE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONOTHERAPY; OBESITY; PATIENT COMPLIANCE; POLYPHARMACY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SUBSTANCE USE; UNITED STATES;

EID: 85019630996     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125316672135     Document Type: Article

References (44)

1. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association.
2. American Psychiatric Association (2002) Practice guideline for the treatment of patients with bipolar disorder (Revision). Am J Psychiatry 159: 1–50.
3. Baek J., Ha K., Yatham L., Chang J., Ha T., Jeon H.. (2014) Pattern of pharmacotherapy by episode types for patients with bipolar disorders and its concordance with treatment guidelines. J Clin Psychopharmacol 34: 577–587.
4. Berger A., Edelsberg J., Bollu V., Alvir J., Dugar A., Joshi A.. (2011) Healthcare utilization and costs in patients beginning pharmacotherapy for generalized anxiety disorder: a retrospective cohort study. BMC Psychiatry 11: 193.
5. Berger A., Edelsberg J., Sanders K., Alvir J., Mychaskiw M., Oster G., (2012) Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study. BMC Psychiatry 12: 99.
6. Biancosino B., Barbui C., Marmai L., Dona S., Grassi L., (2005) Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol 20: 305–309.
7. Blanco C., Laje G., Olfson M., Marcus S., Pincus H., (2002) Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 159: 1005–1010.
8. Bravata D., Ho S., Brass L., Concato J., Scinto J., Meehan T., (2003) Long-term mortality in cerebrovascular disease. Stroke 34: 699–704.
9. Chen H., Mehta S., Aparasu R., Patel A., Ochoa-Perez M., (2014) Comparative effectiveness of monotherapy with mood stabilizers versus second generation (Atypical) antipsychotics for the treatment of bipolar disorder in children and adolescents. Pharmacoepidemiol Drug Saf 23: 299–308.
10. Chen W., Deveaugh-Geiss A., Palmer L., Princic N., Chen Y., (2013) Patterns of atypical antipsychotic therapy use in adults with bipolar I disorder in the USA. Hum Psychopharmacol 28: 428–437.
11. Chen Y., Kang J., Lin C., Wang I., Keller J., Lin H., (2012) Obstructive sleep apnea and the risk of adverse pregnancy outcomes. Am J Obstet Gynecol 206: 136.
12. Colom F., Vieta E., Tacchi M., Sanchez-Moreno J., Scott J., (2005) Identifying and improving non-adherence in bipolar disorders. Bipolar Disord 7(Suppl. 5): 24–31.
13. Crump C., Sundquist K., Winkleby M., Sundquist J., (2013) Comorbidities and mortality in bipolar disorder: a swedish national cohort study. JAMA Psychiatry 70: 931–939.
14. Dassori A., Copeland L., Zeber J., Miller A., (2011) Factors in second-generation antipsychotic switching patterns in a national sample of older veterans with schizophrenia. Psychiatr Serv 62: 47–53.
15. Fagiolini A., Forgione R., Maccari M., Cuomo A., Morana B., Dell’osso M.. (2013) Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord 148: 161–169.
16. Goldberg J., Brooks J., III Kurita K., Hoblyn J., Ghaemi S., Perlis R.. (2009) Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry 70: 155–162.
17. Hassan M., Lage M., (2009) Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. Am J Health Syst Pharm 66: 358–365.
18. IMS Health (2013) IMS Pharmetrics Plus™ Data Dictionary. Plymouth Meeting, PA: IMS Health.
19. IMS Health (2015) National Prescription Audit (NPA). Product Volume by Strength. Plymouth Meeting, PA: IMS Health.
20. Katon W., Lin E., Williams L., Ciechanowski P., Heckbert S., Ludman E.. (2010) Comorbid depression is associated with an increased risk of dementia diagnosis in patients with diabetes: a prospective cohort study. J Gen Intern Med 25: 423–429.
21. Kemp D., (2014) Managing the side effects associated with commonly used treatments for bipolar depression. J Affect Disord 169(Suppl. 1): S34–S44.
22. Kemp D., Gao K., Chan P., Ganocy S., Findling R., Calabrese J., (2010) Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disord 12: 404–413.
23. Kisely S., Smith M., Lawrence D., Maaten S., (2005) Mortality in individuals who have had psychiatric treatment: population-based study in Nova Scotia. Br J Psychiatry 187: 552–558.
24. Krishnan K., (2005) Psychiatric and medical comor-bidities of bipolar disorder. Psychosom Med 67: 1–8.
25. Kupfer D., (2005) The increasing medical burden in bipolar disorder. JAMA 293: 2528–2530.
26. Lage M., Hassan M., (2009) The relationship between antipsychotic medication adherence and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective study. Ann Gen Psychiatry 8: 7.
27. Leboyer M., Kupfer D., (2010) Bipolar disorder: new perspectives in health care and prevention. J Clin Psychiatry 71: 1689–1695.
28. Liang J., Sun L., Muo C., Sung F., Chang S., Kao C., (2011) The analysis of depression and subsequent cancer risk in Taiwan. Cancer Epidemiol Biomarkers Prev 20: 473–475.
29. Livingstone S., Looker H., Hothersall E., Wild S., Lindsay R., Chalmers J.. (2012) Risk of cardiovascular disease and total mortality in adults with Type ype 1 diabetes: scottish registry linkage study. PLoS Med 9: e1001321.
30. Macgregor A., Corson K., Larson G., Shaffer R., Dougherty A., Galarneau M.. (2009) Injury-specific predictors of posttraumatic stress disorder. Injury 40: 1004–1010.
31. Merikangas K., Akiskal H., Angst J., Greenberg P., Hirschfeld R., Petukhova M.. (2007) Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry 64: 543–552.
32. Moreno C., Laje G., Blanco C., Jiang H., Schmidt A., Olfson M., (2007) National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry 64: 1032–1039.
33. National Alliance on Mental Illness (2013) A Primer on Depressive, Bipolar and Anxiety Illnesses: Facts for Policymakers. Arlington, VA: National Alliance on Mental Illness (NAMI) Policy Research Institute.
34. Olfson M., Marcus S., Corey-Lisle P., Tuomari A., Hines P., L’italien G., (2006) Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 163: 1821–1825.
35. Perugi G., Micheli C., Akiskal H., Madaro D., Socci C., Quilici C.. (2000) Polarity of the first episode, clinical characteristics, and course of manic depressive illness: a systematic retrospective investigation of 320 bipolar I patients. Compr Psychiatry 41: 13–18.
36. Schmittdiel J., Adams S., Segal J., Griffin M., Roumie C., Ohnsorg K.. (2014) Novel use and utility of integrated electronic health records to assess rates of prediabetes recognition and treatment: brief report from an integrated electronic health records pilot study. Diabetes Care 37: 565–568.
37. Stephenson J., Tunceli O., Gu T., Eisenberg D., Panish J., Crivera C.. (2012) Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians’ perceptions of adherence vs. pharmacy claims. Int J Clin Pract 66: 565–573.
38. Sunovion (2013) Latuda (lurasidone hydrochloride) [package insert]. Marlborough, MA, USA: Sunovion Pharmaceuticals Inc.
39. Svarstad B., Shireman T., Sweeney J., (2001) Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 52: 805–811.
40. Tidemalm D., Haglund A., Karanti A., Landen M., Runeson B., (2014) Attempted suicide in bipolar disorder: risk factors in a cohort of 6086 patients. PLoS One 9: e94097.
41. Vancampfort D., Vansteelandt K., Correll C., Mitchell A., De Herdt A., Sienaert P.. (2013) Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 170: 265–274.
42. Weiden P., Kozma C., Grogg A., Locklear J., (2004) Partial compliance and risk of rehospitalization among california medicaid patients with schizophrenia. Psychiatr Serv 55: 886–891.
43. Weinstock L., Gaudiano B., Epstein-Lubow G., Tezanos K., Celis-Dehoyos C., Miller I., (2014) Medication burden in bipolar disorder: a chart review of patients at psychiatric hospital admission. Psychiatry Res 216: 24–30.
44. Zhu B., Zhao Z., Ye W., Marciniak M., Swindle R., (2009) The cost of comorbid depression and pain for individuals diagnosed with generalized anxiety disorder. J Nerv Ment Dis 197: 136–139.